Statement of Changes in Beneficial Ownership (4)
July 02 2021 - 09:39AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
GLOCER THOMAS H |
2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc.
[
MRK
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
MERCK & CO., INC., 2000 GALLOPING HILL ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/30/2021 |
(Street)
KENILWORTH, NJ 07033
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | | | | | | | | 5100 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Phantom Stock | (1) | 6/30/2021 | | A | | 112.5113 | | (2) | (2) | Common Stock | 112.5113 | $77.77 | 78357.7946 (3)(4) | D | |
Explanation of Responses: |
(1) | 1-for-1 |
(2) | Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. |
(3) | Holdings include shares acquired in dividend reinvestment transactions. |
(4) | Holdings reflect the adjustment that occurred as of June 2, 2021 in connection with the Organon spin-off as described in the registration statement on Form 10 filed with the SEC for Organon & Co. (the "Form 10"). As reported in the Form 10, each Merck phantom share outstanding under the Merck Deferred Compensation Plan as of immediately prior to the distribution date was converted on the distribution date into an adjusted Merck phantom share with the number of units represented by such award adjusted to preserve the aggregate value of the original Merck phantom shares as measured before and immediately after the distribution. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
GLOCER THOMAS H MERCK & CO., INC. 2000 GALLOPING HILL ROAD KENILWORTH, NJ 07033 | X |
|
|
|
Signatures
|
/s/ Kelly E. W. Grez as Attorney-in-Fact for Thomas H. Glocer | | 7/2/2021 |
**Signature of Reporting Person | Date |
Merck (NYSE:MRK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2023 to Mar 2024